ReviewMolecular medicine (Cambridge, Mass.)2014
Recent developments in the role of high-mobility group box 1 in systemic lupus erythematosus.
Review in Molecular medicine (Cambridge, Mass.), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05193591 (Evaluation of Anti-C1s, Anti-HMGB1 and Anti-C1q Autoantibodies in the Pathogenesis for Patients With Systemic Lupus Erythematosus), which is not on this map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Evaluation of Anti-C1s, Anti-HMGB1 and Anti-C1q Autoantibodies in the Pathogenesis for Patients With Systemic Lupus Erythematosus (SLE)
Who cites it
22 citing papers in PubMed, 53 citations in OpenAlex.
- Ferroptosis: A potential therapeutic target in autoimmune disease (Review).Experimental and therapeutic medicine · 2023Review
- Etanercept ameliorates psoriasis progression through regulating high mobility group box 1 pathway.Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI) · 2023Article
- Identification of NETs-related biomarkers and molecular clusters in systemic lupus erythematosus.Frontiers in immunology · 2023Article
- Complement System and Alarmin HMGB1 Crosstalk: For Better or Worse.Frontiers in immunology · 2022Review
- The Potential Role of Ferroptosis in Systemic Lupus Erythematosus.Frontiers in immunology · 2022Review
- Tuning Monocytes and Macrophages for Personalized Therapy and Diagnostic Challenge in Rheumatoid Arthritis.Cells · 2021Review
- Review
- Article
- HMGB1-modified mesenchymal stem cells attenuate radiation-induced vascular injury possibly via their high motility and facilitation of endothelial differentiation.Stem cell research & therapy · 2019Article
- Programmed Cell Death Pathways in the Pathogenesis of Systemic Lupus Erythematosus.Journal of immunology research · 2019Review
- High Mobility Group Box 1 Influences HSV1716 Spread and Acts as an Adjuvant to Chemotherapy.Viruses · 2018Article
- Article
- Lipoxin A4 and its analog suppress inflammation by modulating HMGB1 translocation and expression in psoriasis.Scientific reports · 2017Article
- Article
- High-mobility group box 1 potentiates antineutrophil cytoplasmic antibody-inducing neutrophil extracellular traps formation.Arthritis research & therapy · 2016Article
- Antibodies against High Mobility Group Box protein-1 (HMGB1) versus other anti-nuclear antibody fine-specificities and disease activity in systemic lupus erythematosus.Arthritis research & therapy · 2015Article
- Endotoxin tolerance in monocytes can be mitigated by α2-interferon.Journal of leukocyte biology · 2015Article
- The Role of Damage-Associated Molecular Patterns in Human Diseases: Part I - Promoting inflammation and immunity.Sultan Qaboos University medical journal · 2015Review
- Expression of HMGB1/RAGE protein in renal carcinoma and its clinical significance.International journal of clinical and experimental pathology · 2015Article
- HMGB1 in health and disease.Molecular aspects of medicine · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
High-mobility group box 1 (HMGB1) is an important molecule for several nuclear processes. Recently, HMGB1 has gained much attention as a damage-associated molecular pattern (DAMP) and has been implicated in the pathogenesis of several (auto)-immune diseases, in particular, systemic lupus erythematosus (SLE). A main pathogenic feature in SLE is the accumulation of apoptotic cells. Since HMGB1 is released from apoptotic cells it has been hypothesized that HMGB1 might fuel the inflammatory processes, as seen in this disease, and play a fundamental role in the pathogenesis. In this review, we discuss evidence in support of the theory that HMGB1 is an important mediator in SLE and may be considered a new autoantigen.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.